Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | HCK | P08631 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5219863 | 0.83 | ESR1 (0.50) | HSD17B10ALOX15TSHRLMNASRC | |
| SCHEMBL5222471 | 0.82 | PDE4A (0.41) | SMN1; SMN2ALDH1A1HSD17B10ALOX15TSHR | |
| SCHEMBL5216625 | 0.79 | ESR1 (0.42) | HSD17B10ALOX15TSHRLMNACMKLR1 | |
| SCHEMBL5379304 | 0.78 | CMKLR1 (0.45) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL395263 | 0.71 | CMKLR1 (0.45) | ALDH1A1HSD17B10ALOX15TSHRHPGD | |
| SCHEMBL5215073 | 0.70 | ESR1 (0.49) | ALDH1A1HSD17B10ALOX15TSHRLMNA | |
| SCHEMBL395096 | 0.70 | CYP1A2 (0.45) | ALDH1A1HSD17B10TSHRHPGDLMNA | |
| SCHEMBL8888577 | 0.69 | KDM4E (0.46) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL1407427 | 0.69 | ESR1 (0.46) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL4194778 | 0.69 | ESR1 (0.46) | SMN1; SMN2ALDH1A1HSD17B10ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1102753-B1 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-6727273-B2 | THERAPY FOR OSTEOPOROSIS, ANTICANCER AGENTS | CHIRON CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040077701-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-20020111374-A1 | Estrogen receptor modulators | CHIRON CORPORATION | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077701-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | SMN1; SMN2 4806/4885NPC1 954/4885RAB9A 2665/4885 |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | ESR1, ESR2, GPER1 | SMN1; SMN2 4806/4885NPC1 954/4885RAB9A 2665/4885 |
| US-20020111374-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | SMN1; SMN2 4806/4885NPC1 954/4885RAB9A 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.